Oncology

For Terri Lynn Shigle, PharmD, the field of hematology-oncology is deeply personal. Having lost loved ones to cancer, she was drawn to a career where she could make a meaningful difference in patient care.

In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.

Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.

Learn how COVID-19 impacted oncology practice from the uptake of telehealth to delays in screening, with key takeaways from leading oncologists.

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.

AI-powered pathology imaging enables a more comprehensive assessment of tumor microenvironments than humans alone could perceive.

A retrospective cohort study found that, of Medicare decedents with advanced cancer, 45% experienced potentially aggressive end-of-life care.

Phase 2 study results revealed NP-G2-044 plus standard of care anti–PD-1 therapy indicated treatment exhibited responses across at least 7 cancer types.

A phase 1/1b trial found that the triplet combination elicited an ORR of 45.5% and a median PFS of 14.5 months in previously untreated clear cell RCC.

Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.

According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.

When pembrolizumab is combined with immunotherapies, the incidence of grade 3 to 5 toxicities increases, especially with anti–CTLA-4 combinations.

“We’ve seen with the initial anti-CTLA-4 ipilimumab experience that, as time went by, we were better at identifying and managing toxicities,” stated Omid Hamad, MD.

Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

A pooled analysis found pembrolizumab has a discontinuation rate of 12.7%, and a major key to handling it is maintaining good communication between the doctor and the patient.

AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

Artificial intelligence may act as a force multiplier, with the automation of menial tasks enabling more time for clinicians to engage with patients.

Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.